Beckman Coulter Purchases Flow Cytometry Assets
A Beckman Coulter spokesperson told IBO that ReaMetrix’s DuraClone dry reagent technology will be provided as a service for customers as part of the company’s Custom Design Service business. ReaMetrix will continue to operate in India, concentrating on developing affordable diagnostic products. The company has 25 employees.
Indianapolis, IN 8/1/13—Beckman Coulter Life Sciences has acquired the flow cytometry business assets of ReaMetrix India. The acquisition will expand Beckman Coulter’s flow cytometry reagent offerings, adding ReaMetrix’s dry temperature-stable reagents for clinical research and HIV monitoring. “This acquisition provides both immediate opportunity and long-term value,” said Mario Koksch, vice president and general manager of Beckman Coulter’s Cytometry Business Unit. “The simplification of customer workflows will be dramatic.” ReaMetrix’s reagents have received CE approval for IVD use in Europe.
